Dallas Wood Dylan griFFin matt Nicholson HYPERKINESIA Dallas Wood Dylan griFFin matt Nicholson

Current Go-To treatment for PD Levodopa (L-DOPA) L-DOPA- a precursor to dopamine L-DOPA’s size allows it to cross the blood-brain barrier, and enter the Basal Ganglia (where DOPA decarboxylase is and increases dopamine levels)

Parkinson’s Disease Dopaminergic neurons are degenerated, thus an increase in dopamine will reverse the negative effects of PD

Co-Treatment L-DOPA + MAO-I If we inhibit MOA with MOA-I then dopamine concentration will increase MOA-I inhibits the dopamine regulatory enzyme, monoamine oxidase (MAO) MAO- deaminates monoamines (ie, dopamine) if levels are too high Thus, the co-treatment will lead to an overall boost of dopamine

Co-Treatment effects With the long term co-treatment of MAO-I and L-DOPA, patients may develop hyperkinesia HYPERKINESIA= an increase in muscular activity (excessive/abnormal)

Nitric Oxide (NO) Is a gaseous signaling molecule, known to play a big role in the B.G. to enhance dopamine synthesis Having too much/too little is bad Too much= oxidative stress The Co-treatment is shown to increase NO in the B.G.

nNOSI Can cause dyskinesia symptoms to be reduced